Compare Godaddy Inc (GDDY) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Godaddy Inc vs Tango Therapeutics Inc. — how do they compare? Godaddy Inc trades at $103.39 (market cap $13.05B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Godaddy Inc is far larger — about 3.5× Tango Therapeutics Inc.'s market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, Godaddy Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Godaddy Inc for 65 Days and Tango Therapeutics Inc. for 0 Days on average.
| GDDY | TNGX | |
|---|---|---|
Market Cap | $13.05B | $3.75B |
Volume | 1,123,303 | 9,619,106 |
Sector | Technology | Health |
52-Week High | $135.18 | $32.90 |
52-Week Low | $75.07 | $7.50 |
Typical Hold Time | 65 Days | 0 Days |
Enterprise Value | $15.73B | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GoDaddy (GDDY) trades at $103.36, up 1.02% today, with a bullish technical signal from moving averages. The company reported revenue of $4.95B in 2025 and net income of $875M, with consistent earnings beats in recent quarters. However, the stock faces headwinds from a securities class action lawsuit alleging misrepresentations about domain contract terms, as reported by multiple law firms in late September 2026.
The outlook is mixed: strong profitability and earnings momentum support upside, but legal risks and a consensus price target below the current price suggest caution. Investors should weigh robust fundamentals against litigation overhangs and monitor Q3 2026 earnings for further direction.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Godaddy Inc
GoDaddy is a provider of domain registration and aftermarket services, website hosting, security, design, and business productivity tools, commerce solutions, and domain registry services. The company primarily targets micro- to small businesses, website design professionals, registrar peers, and domain investors. Since acquiring payment processing platform Poynt in 2021, the company has expanded into omnicommerce solutions, including offering an online payment gateway and offline point-of-sale devices.
Read more on GDDY →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
